BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2273 related articles for article (PubMed ID: 17302598)

  • 1. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.
    Matas AJ; Kandaswamy R; Humar A; Payne WD; Dunn DL; Najarian JS; Gruessner RW; Gillingham KJ; McHugh LE; Sutherland DE
    Ann Surg; 2004 Sep; 240(3):510-6; discussion 516-7. PubMed ID: 15319722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.
    Shaffer D; Langone A; Nylander WA; Goral S; Kizilisik AT; Helderman JH
    Clin Transplant; 2003; 17 Suppl 9():31-4. PubMed ID: 12795665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications.
    Shaffer D; Kizilisik AT; Feurer I; Nylander WA; Helderman JH; Langone AJ; Schaefer HM
    Transplant Proc; 2006 Dec; 38(10):3464-5. PubMed ID: 17175304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
    Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
    Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a calcineurin-inhibitor-free immunosuppressive protocol in renal transplant recipients of expanded criteria deceased donors.
    Re LS; Rial MC; Guardia OE; Galdo MT; Casadei DH
    Transplant Proc; 2006 Dec; 38(10):3468-9. PubMed ID: 17175306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.
    Rajab A; Pelletier RP; Henry ML; Ferguson RM
    Clin Transplant; 2006; 20(5):537-46. PubMed ID: 16968478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients.
    Khwaja K; Asolati M; Harmon J; Melancon JK; Dunn T; Gillingham K; Kandaswamy R; Humar A; Gruessner R; Payne W; Najarian J; Dunn D; Sutherland D; Matas AJ
    Am J Transplant; 2004 Jun; 4(6):980-7. PubMed ID: 15147433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
    Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
    Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term results under three different immunosuppressive regimens at one center.
    Schaefer HM; Kizilisik AT; Feurer I; Nylander WA; Langone AJ; Helderman JH; Shaffer D
    Transplant Proc; 2006 Dec; 38(10):3466-7. PubMed ID: 17175305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 114.